Overview
- 6 inspections across 6 sites are on record.
- 39 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2022-11-03.
At a glance
Inspections
6
Sites
6
Observations
39
Career since
Feb 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| ChiRhoClin, Inc | 3 Nov 2022 | Human Drugs | View 483 → |
| Steri-Pharma, LLC | 4 Oct 2022 | Human Drugs | View 483 → |
| New Dawn Manufacturing | 29 Aug 2022 | Human Drugs | |
| Akorn Inc. | 17 May 2022 | Human Drugs | View 483 → |
| Arnold Professional Pharmacy | 18 Mar 2022 | Human Drugs | View 483 → |
Sites inspected
ChiRhoClin, IncBurtonsville, United States1 insp.
Steri-Pharma, LLCSyracuse, United States1 insp.
New Dawn ManufacturingUpper Marlboro, United States1 insp.
Akorn Inc.Somerset, United States1 insp.
Arnold Professional PharmacyArnold, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Mindy M Chou3 shared
Marcellinus D Dordunoo2 shared
Pushpa S Jayasekara1 shared
Elaine E Gilfillan1 shared
Amy N Chen1 shared
Daniel J Min1 shared
Roseline N Boateng1 shared
Nicholas A Violand1 shared
Ko U Min1 shared
Sena G Dissmeyer1 shared
Full investigator report
Get the verbatim findings behind Natasha Gupta's 39 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site